Oncology: Risk Stratification and Treatment Modalities of Acute Myeloid Leukemia (AML) - Presented by Tara Gregory, MD - Hematology/Oncologist
Enduring   |   1 Credit(s)

LEARNING OBJECTIVES Following the presentation, each participant should be able to: 1.Explain the risk stratification of AML. 2.Describe the utility and role of allogeneic stem cell transplant in the transplant eligible patient. 3.Explain treatment options and goals for the stem cell ineligible patient.

Release Date: 8/06/2014   |   End Date: 8/06/2017

Presented by Tara Gregory, MD - Hematology/Oncology - Risk Stratification and Treatment Modalities of Acute Myeloid Leukemia (AML)

Presbyterian/St. Luke’s Medical Center

  • Release date: August 6, 2014
  • Expiration date: August 6, 2017
  • Estimated time to complete activity:1 hour


For all questions/concerns, contact the HealthONE Office of Continuing Medical Education at 303.584.2235 or stacy.weiss@healthonecares.com  


Policy on Privacy and Confidentiality


DISCLOSURES

HealthONE CME assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by HealthONE CME for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HealthONE CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity. The faculty members have reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.

  • Dr. Gregory has no relevant conflicts of interest to report.


The following members of the Denver CME Committee hereby state that they or their spouse/life partner do not have any financial relationships or relationships in any amount during the past 12 months to products, devices, or any commercial interests related to the content of this CE activity:

  • Stacy Weiss, MA
  • Lindy Garvin
  • Gary Winfield, MD
  • Regina Brooks, CCMEP
  • Kevin Roberts
  • Holly Bodine
  • Ashley Rees-Jones

The following members of the Planning Committee hereby state that they or their spouse/life partner do not have any financial relationships or relationships in any amount during the past 12 months to products, devices, or any commercial interests related to the content of this CE activity:

  • Tara Gregory, MD
  • Stacy Weiss, MA
  • Sharon Fresques

The following HealthONE clinical content reviewers hereby state that they or their spouse/life partner do not have any financial relationships or relationships in any amount during the past 12 months to products, devices, or any commercial interests related to the content of this CE activity:

  • Stacy Weiss, MA

LEARNING OBJECTIVES 

Following the presentation, each participant should be able to:

  1. Explain the risk stratification of AML.
  2. Describe the utility and role of allogeneic stem cell transplant in the transplant eligible patient.
  3. Explain treatment options and goals for the stem cell ineligible patient.

 

 

LEVEL OF EVIDENCE 

HealthONE CME has designated 3 Levels of Evidence for CME presentations:

  1. Evidence mainly from randomized or non-randomized, well designed controlled trials; well-designed cohort or case-controlled analytic studies.
  2. Evidence from multiple studies with or without the intervention being targeted, meta-analysis, opinions of respected authorities or expert panels, or information based on case reports.
  3. Uncontrolled experiments, descriptive studies, presenter’s clinical experience/opinion or research in progress.
  • The majority of this presentation will be based on Level 1, 2 and 3 Evidence. 

 


ACCREDITATION & CREDIT DESIGNATION STATEMENTS 

HealthONE CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

HealthONE CME designates this enduring activity for a maximum of  1 AMA PRA Category I Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

DISCLAIMER 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 
 

UNLABELED/UNAPPROVED USES NOTICE 

In accordance with the ACCME Essential Areas and Policies, as well as, the Standards for Commercial Support, the audience is advised that this continuing medical education  activity may contain references to unlabeled or unapproved uses of drugs or devices.Specific medicines discussed in this program may not yet be specifically approved and/or may not be specified to be used as indicated by the speakers. Before prescribing any medication, review the complete prescribing information, including indications, contraindications, warnings, precautions and adverse effects.

POST-TEST and PROGRAM EVALUATION 

Please take a few minutes to complete the evaluation form. This information is used not only to evaluate the present symposium, but also to plan for future programs. Successful completion of the post-test and evaluation generates your CME certificate.